Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34).

Manuel Alfonso Patarroyo; Alvaro Mongui; Diana I. Angel; Gina Gallego; Claudia Reyes; Paola Martinez; Felipe Guhl

Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34).

Manuel Alfonso Patarroyo, Alvaro Mongui, Diana I. Angel, Gina Gallego, Claudia Reyes, Paola Martinez, Felipe Guhl

School of Medicine and Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.

Original language	English (US)
Pages (from-to)	415-421
Number of pages	17
Journal	Vaccine
Volume	28
Issue number	2
State	Published - Dec 11 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.sciencedirect.com/science/article/pii/S0264410X0901562X?via%3Dihub

Cite this

@article{03f87144e91f4295a4e202c92db650e2,

title = "Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34).",

abstract = "This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.",

author = "Patarroyo, {Manuel Alfonso} and Alvaro Mongui and Angel, {Diana I.} and Gina Gallego and Claudia Reyes and Paola Martinez and Felipe Guhl",

year = "2009",

month = dec,

day = "11",

language = "English (US)",

volume = "28",

pages = "415--421 ",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34).

AU - Patarroyo, Manuel Alfonso

AU - Mongui, Alvaro

AU - Angel, Diana I.

AU - Gallego, Gina

AU - Reyes, Claudia

AU - Martinez, Paola

AU - Guhl, Felipe

PY - 2009/12/11

Y1 - 2009/12/11

N2 - This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.

AB - This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.

M3 - Article

SN - 0264-410X

VL - 28

SP - 415

EP - 421

JO - Vaccine

JF - Vaccine

IS - 2

ER -

Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34).

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this